Indian Pharmaceutical Formulations Industry Report, 2008-2009
  • Apr/2009
  • Hard Copy
  • USD $899
  • Pages:119
  • Single User License
    (PDF Unprintable)       
  • USD $999
  • Code: ZQ002
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,499
  • Hard Copy + Single User License
  • USD $1,099

India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more than 400 kinds of API (Active Pharmaceutical Ingredient) and over 60,000 kinds of pharmaceutical formulations are available in Indian market, and 60% of API and 25% of patent medicine are exported.

In terms of the medical product value, India ranks at the fourteenth worldwide. Over half output of the top ten Indian pharmaceutical companies are exported to oversea markets each year, with a total value of US $5.8 billion approximately.

Indian pharmaceutical formulations are mainly exported to the U.S.A, western Europe and Russia, are basically the genetic drugs with expired patent, especially the primary ones such as Fluoxetine, Ciprofloxacin and Omeprazole etc. However, India also engaged in the innovations. For example, Lupin Laboratories self-developed the cefotaxime without infringing the patent of Takeda Pharmaceuticals.

Apart from the constant expansion in the U.S.A and European markets, Indian pharmaceutical companies also target on the new markets such as China, Japan, Brazil and Mexico etc. in order to the decentralize of market risks. According to the Mckinsey, the Indian pharmaceutical market value will reach as high as US $25 billion in 2010.

India has numerous talented scientists who specialized in the chemicals and pharmaceutical It has close contact with the FDA and other international supervision institutions. Furthermore, it also has high-quality pharmaceutical production facilities. Compared to the developed countries, it is easier for India to conduct the clinical trial and also a lower cost. India also has strong IT capability to support the clinical data management.

The labor cost in India is 70% lower than in the U.S.A. The expenditure for establishing a pharmaceutical factory with FDA approval in India is only 70% of that in the U.S.A. The multinational pharmaceutical companies have already outsourced the API, intermediates and generic drugs production to India and China etc.

1. Overview of Pharmaceutical Formulations Industry in India
1.1 Introduction to Pharmaceutical Formulations
1.2 Current Status and Prospects of Global Pharmaceutical Formulations Industry
1.3 Current Status and Prospects of Indian Pharmaceutical Formulations Industry

2.Analysis on Major Pharmaceutical Formulations Producers in India
2.1 Ranbaxy Laboratories Ltd
2.2 Dr Reddys Laboratories Ltd
2.3 Cipla Ltd
2.4 Sun Pharmaceuticals Industries Ltd
2.5 Piramal Healthcare Ltd
2.6 Wockhardt Ltd
2.7 Cadila Healthcare Ltd
2.8 Matrix Laboratories Ltd
2.9 GlaxoSmithkline Pharmaceutical Ltd
2.10 Torrent Pharmaceuticals Ltd
2.11 IPCA Laboratories Ltd
2.12 Pfizer Ltd
2.13 Alembic Ltd
2.14 Aventis Pharma Ltd
2.15 Panacea Biotec Ltd
2.16 Strides Arcolab Ltd
2.17 Unichem Laboratories Ltd
2.18 Emami Ltd
2.19 Novartis India Ltd
2.20 Abbott India Ltd
2.21 JB Chemicals & Pharmaceuticals Ltd
2.22 Elder Pharmaceuticals Ltd
2.23 FDC Ltd
2.24 Wyeth Ltd
2.25 Natco Pharma Ltd
2.26 Ajanta Pharma Ltd
2.27Astrazeneca Pharma India Ltd
2.28 Twilight Litaka Pharma Ltd
2.29 Granules India Ltd
2.30 TTK Health Care Ltd

3. Pharmaceutical Competitiveness Contrast between India and China 
3.1  Contrast of Industrial Status Quo
3.2  Contrast of R&D 
3.3  Contrast of Product Structure 
3.4  Contrast of International Certification 
3.5  Contrast of International Market Exploitation
Value of drugs going off patent in the world.2006-2011
Revenue and net profit of Ranbaxy.2003-2007
Business model of Ranbaxy,2007
Global operation of Ranbaxy,2007
Europe-Key Markets of Ranbaxy,2007
Emerging markets of Ranbaxy,2007
Geographic sales split of Ranbaxy, 2007
Inorganic strategy of Ranbaxy,2007
Aspirations of Ranbaxy (2012)
Revenue and net profit of Dr. Reddy,2003-2007
Consolidated Business-Wise Performance of Dr. Reddy
Geographic Mix of Formulations of Dr. Reddy
Therapy-wise distribution (based on FY 05-06 performance)
Revenue and net profit of Sun Pharmaceuticals,2004-2008
Products structure of Sun Pharmaceuticals, 2009
Ranks based on prescription share of Sun Pharmaceuticals
Revenue composition of Sun Pharmaceuticals,2009
Growing revenue of Sun Pharmaceuticals,2003-2007
Sustained profitability of Sun Pharmaceuticals,2003-2007
Successful acquisitions of Sun Pharmaceuticals,1995-2003
Peer comparison of Sun Pharmaceuticals,1992-2007
Strategy and approach of Sun Pharmaceuticals,2009
Revenue and net profit of Piramal,2004-2008
Branded Formulations–Consolidated Q3-FY2009
Brands holding by Piramal,2009
Drug life-cycle of Piramal,2009
Manufacturing market of Piramal,2009
Global outsourcing partner,2009
Strategy of Piramal,2009
Revenue and net profit of Wockhardt.2003-2007
Biopharmaceuticals value chain of Wockhardt,2008
Sales Revenues and Profits of Wockhardt,1992-2007
Global operations of Wockhardt,2008
Operation distribution of Wockhardt in 1992, 2000 and 2007
Balanced portfolio of Wockhardt,2008
Eight acquisitions of Wockhardt,1997-2007
Revenue and Net Profit of Cadila from 2004 to 2008
Revenue break-up of Cadila
financial highlights of Cadila, 2005 -2008
Research focus of Cadila
Strong brand of Cadila
Scheme of Cadila for 2009
Strategies for growth momentum of Cadila
Revenue and Net Profit of Matrix,2004-2008
Capacities and production of Matrix,2006-2007
Three principal products of Matrix,2007
Shareholding pattern of Matrix, 2008
Product group-wise performance of Matrix
Revenue and Net Profit of GlaxoSmithkline,2004-2008
Current Products of GlaxoSmithKline
New Pharma Products
Net Sales of GlaxoSmithkline(by price category),2007-2008
Net Sales of GlaxoSmithkline(by segments),2007-2008
Revenue and net profit of Torrent, 2004-2008
Information in case of imported technology,2005-2007
Therapeutic area sales of Torrent,2006-2007
Sales of Torrent Pharmaceuticals by regions,2006-2008
Revenue and Net Profit of IPCA , 2004-2008
Financial highlights of IPCA from 1998 to 2008
Break-up of pharmaceutical sales of IPCA (by products)
Domestic branded formulations groupwise contribution of IPCA,2007-2008
Continentwise exports of IPCA
Distribution of Shareholding of IPCA as on March 31,2008
Revenue and Net Profit of Pfizer, 2004-2008
Revenue and net profit of Alembic,2004- 2008
New products lauched in respetive therapy segment of Alembic
Key products of animal-health of Alembic
Distribution of shareholding of Alembic
Contribution to tatal domestic formulation sales of Alembic
Financial highlight of Alembic,2007-2008
Sales and income from operations
Revenue and net profit of Aventis,2004- 2008
The break up of Net Sales
Revenue and net profit of Panacea Biotec,2004 -2008
Brand standing and market share of Panacea
Shareholding pattern of Panacea as on March 31, 2008
Gross turnover of Panacea for the financial year 1997, 2002 and 2007
Strategy of Panacea
Revenue and net profit of Strides from 2004 to 2008
Business model of Strides
Revenue attributable to location of customers of Strides
Revenue Geographical distribution of Strides for 2008
Strategy of Strides
Revenue and net profit of Unichem,2004-2008
Comparison of power brands of Unichem,2006-2008
Shareholding pattern as on March 31, 2008
Financial highlights of Unichem,2005-2008
Operational statement of Emami
Snapshot of Emami’s power brands
Highlights of Emami for the financial year 2008
Revenue and earnings performance of Emami from 2004 to 2008
Peer group valuation for financial year 2008
Strategy of Emami
Revenue and net profit of NIL,2004 - 2008
Product sales of NIL in 2008
Sales of Pharmaceutical products by regions, 2008
Products launched by NIL in 2008
Existing Emerging Markets for NIL
NIL’s Consistent strategy for 2009
Revenue and net profit of Abbott,2004 - 2008
Sales of Pharmaceutical Formulations of Abbott in 2008
Revenue and net profit of JBCPL,2004 - 2008
JBCPL Composition of Sales (Formulations & APIs)
JBCPL Composition of Sales (Formulations & APIs)
Status of JBCPL Product Registrations
Revenue and net profit of Elder from 2004 to 2008
Products of Elder
The main fanancial datas of Elder
Stocks and sales of finished goods of Elder
Revenue and assets of Elder,2007-2008
The main fanancial datas of FDC,2007 - 2008
Revenue and assets of FDC
Revenue and net profit of Wyeth,2004- 2008
Revenue and net profit of Natco, 2004-2008
Shareholding pattern of Natco
Revenues of Natco by divisions,2006-2008
Revenue and net profit of Ajanta,2007-2008
Income from operations of Ajanta,,2002-2007
Segment Wise Revenue, Results and Capital Employed of AstraZeneca
Revenue and net profit of Twilight, 2007 -2008
Shareholding pattern of Twilight as on March 31, 2007
Revenue and net profit of Granules,2004 -2008
Financial analysis of Granules in 2007-2008
Growing API and PFI business of Granules
Geographic break-up of revenues from key markets of Granules in 2007-2008
Budget measures of Granules
Revenue and net profit of TTK,2007-2008
Segmentwise revenue and results of TTK, 2006- 2008

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Independent Clinical Laboratory Industry Report,2013-2015

Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clini...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

China Pharmaceutical Equipment Industry Report, 2011-2012

In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to Chin...

China Animal Vaccine Industry Report, 2010-2011

China animal vaccine industry has been fast-growing. The market maintained an average annual growth rate up to 13.6% in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0% YoY. With the in...

China Human Vaccine Industry Report, 2010-2011

With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号